| Literature DB >> 32761725 |
Liubov M Lifshits1, John A Roque1,2, Houston D Cole1, Randolph P Thummel3, Colin G Cameron1, Sherri A McFarland1,2.
Abstract
The design of near-infrared (NIR)-active photosensitizers (PSs) for light-based cancer treatments such as photodynamic therapy (PDT) has been a challenge. While several NIR-RuII scaffolds have been reported, this approach has not been proven in cells. This is the first report of NIR-RuII PSs that are phototoxic to cancer cells, including highly pigmented B16F10 melanoma cells. The PS family incorporated a bis(1,8-naphthyridine)-based ligand (tpbn), a bidentate thiophene-based ligand (nT; n=0-4), and a monodentate 4-picoline ligand (4-pic). All compounds absorbed light >800 nm with maxima near 730 nm. Transient absorption (TA) measurements indicated that n=4 thiophene rings (4T) positioned the PDT-active triplet intraligand charge transfer (3 ILCT) excited state in energetic proximity to the lowest-lying triplet metal-to-ligand charge transfer (3 MLCT). 4T had low-micromolar phototoxicity with PIvis and PI733nm values as large as 90 and 12, respectively. Spectroscopic studies suggested that the longer-lived (τTA =3-6 μs) 3 ILCT state was accessible from the 3 MLCT state, but energetically uphill in the overall photophysics. The study highlights that phototoxic effects can be achieved with NIR-absorbing RuII PSs as long as the reactive 3 ILCT states are energetically accessible from the low-energy 3 MLCT states. It also demonstrates that tissue-penetrating NIR light can be used to activate the PSs in highly pigmented cells where melanin attenuates shorter wavelengths of light.Entities:
Keywords: intraligand charge-transfer; melanoma; near-infrared (NIR) photosensitizers; photodynamic therapy; ruthenium anticancer agents
Mesh:
Substances:
Year: 2020 PMID: 32761725 PMCID: PMC7736147 DOI: 10.1002/cbic.202000419
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164